Novartis Ag

Aurigene Discovery Technologies Limited

Aurigene Oncology Limited

Chetan Pandit

Mark G Bock

Susanta Samajdar

Ramulu Poddutoori

Subhendu Mukherjee

Rajeev Goswami

Clive McCarthy

Dirk Behnke

Vinod Shashikant Chaudhari

Claudia Betschart

Henrik Moebitz

Simona Cotesta

Sangamesh Badiger

Dinesh Chikkanna

Bharat Lagu

Jürgen Wagner

Thomas Ullrich

Silvio Ofner

Samuel Hintermann

Murali Chebrolu

Sanjita Sasmal

Jürgen Hans-Hermann Hinrichs

Ramulu Poddutorri

Arndt Meyer

Ravi Kotrabasaiah Ujjinamatada

Mark Gary Bock

Sangamesch Badiger

Simona Costesta

The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Substituted tetrahydroquinolinone compounds as ROR gamma modulators

The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.

Substituted heterocyclyl derivatives as CDK inhibitors

The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as ROR&#x3b3; modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by ROR&#x3b3; receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Pyrazoline derivatives and their use as selective androgen receptor modulators

The invention relates to compound of the formula (I') in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. 

Disubstituted heteroaryl-fused pyridines

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation). 

Heterocyclic sulfonamide derivatives

The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. 

Diaza-spiro[5.5]undecanes

The present invention relates to compounds of Formula I where R, R, X, R, R, W, R, R, and Rare as defined herein as well as pharmaceutically acceptable salts thereof. The compounds have been shown to act as MEK inhibitors which may be useful in the treatment of hyperproliferative diseases, like cancer and inflammation.

Growing community of inventors

Bengaluru, India

Chetan Pandit